– Seven Abstracts Selected for Poster
Presentations –
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a
biopharmaceutical company focused on commercializing its novel
tetracycline XERAVA™ (eravacycline for injection) to treat serious
and life-threatening infections, today announced that data on
XERAVA will be featured in seven poster presentations at the
Infectious Disease Society of America’s (IDSA) Infectious Disease
Week (IDWeek) 2019, taking place October 2-6 in Washington, DC, at
the Walter E. Washington Convention Center.
The details for the data presentations at IDWeek are as
follows:
XERAVA Poster Presentations
Poster title: Comparative Evaluation of ETEST® ERV*
bioMérieux with the CLSI Broth Microdilution Method for
Eravacycline MIC Determination Authors: Sauvonnet V, Fyfe C,
Bouvier M, Fontaine S, Halimi D, Martelin R, Zambardi G Date and
time: Thursday, October 3 from 12:15 p.m. – 1:30 p.m. ET
Location: Hall B + C Poster number: 644 Session
information: New Diagnostics
Poster title: In vitro Activity of Eravacycline, a New
Tetracycline Analog, and Comparators Against the Six Most Commonly
Isolated Ribotypes of Clostridioides difficile Authors:
Basseres E, Miranda J, Gonzales-Luna A, Carlson T, Rashid T, Alam
MJ, Garey K Date and time: Thursday, October 3 from 12:15
p.m. – 1:30 p.m. ET Location: Hall B + C Poster
number: 688 Session information: Novel Antimicrobials
and Approaches Against Resistant Bugs
Poster title: In vitro Activity and Performance of
Available Susceptibility Testing Methods for Eravacycline Against
Carbapenem-Resistant Enterobacteriaceae Authors: Jones C,
Kline E, Nguyen MH, Clancy C, Shields R Date and time:
Thursday, October 3 from 12:15 p.m. – 1:30 p.m. ET Location:
Hall B + C Poster number: 710 Session information:
Novel Antimicrobials and Approaches Against Resistant Bugs
Poster title: Activity of Eravacycline Against
Contemporary Gram-negative Clinical Isolates from New York City
Hospitals Authors: Iregui A, Khan Z, Landman D, Quale J
Date and time: Thursday, October 3 from 12:15 p.m. – 1:30
p.m. ET Location: Hall B + C Poster number: 728
Session information: Novel Antimicrobials and Approaches
Against Resistant Bugs
Poster title: Multicenter Evaluation of Eravacycline MIC
Results for Enterobacteriaceae Using MicroScan Dried Gram-Negative
MIC Panels Authors: Traczewski M, Beasley D, Harrington A,
DesJarlais S, Garner O, Hastey C, Brookman R, Lockett Z, Chau J,
Zimmer B Date and time: Saturday, October 5 from 12:15 p.m.
– 1:30 p.m. ET Location: Hall B + C Poster number:
2132 Session information: Bacterial Diagnostics
Poster title: Predictors of Empiric Carbapenem Therapy in
Complicated Intra-Abdominal Infections in the US, 2013-2017: A
Retrospective Cohort Study Authors: Zilberberg M, Nathanson
B, Lawrence K, Johnson C, Ditch K, Olesky M, Shorr A Date and
time: Saturday, October 5 from 12:15 p.m. – 1:30 p.m. ET
Location: Hall B + C Poster number: 2259 Session
information: Clinical Outcomes of Infections with Resistant
Organisms
Poster title: An Evaluation of Empiric Treatment Patterns
for Adult Patients with Community-Onset “Low-Risk” Complicated
Intra-Abdominal Infections Across US Hospitals Authors:
Lodise T, Izmailyan S, Olesky M, Lawrence K, Tsai L Date and
time: Saturday, October 5 from 12:15 p.m. – 1:30 p.m. ET
Location: Hall B + C Poster number: 2264 Session
information: Clinical Outcomes of Infections with Resistant
Organisms
Additional Activities
- Tetraphase will host a XERAVA exhibit booth (#1125) at IDWeek
2019 during exhibit hours: Thursday, October 4; from 11:45 a.m. –
6:00 p.m. ET; Friday, October 5 from 10:00 a.m. – 4:00 p.m. ET; and
Saturday, October 6 from 10:00 a.m. – 2:00 p.m. ET. Tetraphase
Medical Affairs also will be present at booth #1125 during exhibit
hours.
IDWeek is the combined annual meeting of the Infectious Diseases
Society of America (IDSA), the Society for Healthcare Epidemiology
of America (SHEA), the HIV Medicine Association (HIVMA), and the
Pediatric Infectious Diseases Society (PIDS). Full abstracts can be
found on the IDWeek website at http://www.idweek.org/.
About XERAVA™ XERAVA (eravacycline for injection)
is a tetracycline class antibacterial indicated for the treatment
of complicated intra-abdominal infections in patients 18 years of
age and older. XERAVA was investigated for the treatment of cIAI as
part of the Company's IGNITE (Investigating
Gram-Negative Infections Treated with
Eravacycline) phase 3 programs. In the first pivotal phase 3
trial in patients with cIAI, twice-daily intravenous (IV) XERAVA
met the primary endpoint by demonstrating statistical
non-inferiority of clinical response compared to ertapenem and was
well-tolerated. In the second phase 3 clinical trial in patients
with cIAI, twice-daily IV XERAVA met the primary endpoint by
demonstrating statistical non-inferiority of clinical response
compared to meropenem and was well-tolerated. In both trials,
XERAVA achieved high cure rates in patients with Gram-negative
pathogens, including resistant isolates.
Important Safety Information
To report SUSPECTED ADVERSE REACTIONS, contact Tetraphase
Pharmaceuticals Inc., at 1-833-7-XERAVA (1-833-793-7282) or FDA at
1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full prescribing information for XERAVA at
www.XERAVA.com.
About Tetraphase Pharmaceuticals, Inc. Tetraphase
Pharmaceuticals, Inc., is a biopharmaceutical company using its
proprietary chemistry technology to create novel tetracyclines for
serious and life-threatening conditions, including infections
caused by many of the multidrug-resistant bacteria highlighted as
urgent public health threats by the World Health Organization and
the Centers for Disease Control and Prevention. The Company has
created more than 3,000 novel tetracycline compounds using its
proprietary technology platform. Tetraphase's lead product XERAVA™
is approved for the treatment of complicated intra-abdominal
infections by the U.S. Food and Drug Administration and the
European Medicines Agency. The Company’s pipeline also includes
antibiotics TP-271 and TP-6076, which are Phase 2 ready, and
TP-2846, which is in preclinical testing for acute myeloid
leukemia. The Company intends to out license its pipeline
candidates. Please visit www.tphase.com for more company
information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190925005261/en/
Media and Investor Contact: Argot Partners Maeve
Conneighton 212-600-1902 maeve@argotpartners.com
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Jul 2023 to Jul 2024